DermTech Announces Response to COVID-19

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today released the following letter from its CEO John Dobak, M.D.:

We at DermTech are monitoring the COVID-19 pandemic daily. In these uncertain times, the health and safety of our employees and other stakeholders is a top priority. In an effort to limit the spread of COVID-19, we are managing our staffing and travel as guided by the CDC, OSHA, and state and local governments. We have implemented a work from home policy for those employees who can do so to minimize our in-office staff. Our patient-focused teams continue to operate normally, following appropriate safety procedures including, but not limited to: social distancing, emphasizing proper respiratory etiquette and hand hygiene, staggered shifts, requiring sick employees to stay home, and frequent environmental cleaning. Our field-based sales force has suspended face-to-face interactions with healthcare clinicians and we have implemented tele-sales calls.

Because providing test results for early melanoma detection is imperative, our lab is currently fully operational, and we are receiving and analyzing samples. Across healthcare, non-essential medical visits are being postponed, which is impacting in-office clinical appointments. However, we believe that assessing an atypical mole for melanoma should be considered essential, and as such we are evaluating all opportunities to make our test available to patients and ensure timely results.

While we have minimized disruption to our laboratory operations, we do expect to delay spending in areas not critical to patient care. This will ensure we have the financial flexibility to meet future patient and corporate needs.

We will continue to keep our stakeholders updated on our efforts as the COVID-19 pandemic situation evolves. We will make any further updates related to COVID-19 available through postings on our website at www.DermTech.com.

We are committed to supporting our patients and healthcare clinicians during this difficult time and thank you for your continued trust.

Sincerely,

John Dobak, M.D.
CEO
DermTech

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.